

Financial Tear Sheet

Corporate Profile

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other *in vitro* diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.



OraSure Technologies is the leading supplier of oral-fluid collection devices and *in vitro* diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, *in vitro* diagnostic tests, and other medical devices.



Usage Terms and Disclaimers

Your usage of this Web site and the information and materials contained therein are subject to the disclaimers and other provisions set forth in the Web site, under Usage Terms, Update Notice and Privacy Policy. Links to these provisions are located at the bottom of each page of this Web site.

Stock Performance

OSUR (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$21.71
Change (%)	▲ 0.20 (0.93%)
Volume	481,349
52 Week Low	\$8.39
Market Cap	\$1,316,675,114
Rolling EPS	0.52
PE Ratio	41.4068
Shares Outstanding	60,648,324

Data as of 01/19/18 4:00 p.m. ET



Recent Headlines & Events

01/17/18 - 6:01 a.m.
[OraSure Technologies Earnings Conference Call Invitation](#)

01/05/18 - 6:00 a.m.
[OraSure Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

01/04/18 - 6:01 a.m.
[OraSure Technologies Announces Management Succession Plan](#)

Date	Title
02/07/18 5:00 p.m. ET	Q4 2017 OraSure Technologies, Inc. Earnings Conference Call
05/08/18 10:00 a.m. ET	OraSure Technologies, Inc. 2018 Annual Meeting of Stockholders

Analyst Estimates / Ratings

Mean Recommendation: 1.8



Sell

Strong Buy

Unable to fulfill request.

SEC Filings

Filing Date	Form
01/19/18	SC 13G/A
01/18/18	4
01/04/18	8-K
12/21/17	8-K

Executive Officers

- [Douglas A. Michels](#) President and Chief Executive Officer
- [Ronald H. Spair](#) Chief Operating Officer and Chief Financial Officer
- [Tony Zezzo](#) Executive Vice President, Business Unit Leader, Infectious Disease
- [Jack E. Jerrett](#) Senior Vice President, General Counsel and Secretary
- [Mark L. Kuna](#) Senior Vice President, Finance, Controller and Assistant Secretary
- [Nancy J. McLane](#) Senior Vice President, Operations
- [Michael Reed, Ph.D](#) Senior Vice President, Research and Development and Chief Science Officer
- [Brian Smith](#) Senior Vice President, Business Unit leader, Molecular Solutions
- [Kathleen Weber](#) Senior Vice President and General Manager, Consumer Products

Data provided by Nasdaq. Minimum 15 minutes delayed.

Minimum 20 minutes delayed